


**Listing of the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Claim 1.** (original) A method for reducing inflammation in a subject, the method comprising administering an anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I



(I)

or a pharmaceutically acceptable salt thereof to the subject in need of such treatment.

**Claim 2.** (original) The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is an acid addition salt.

**Claim 3.** (original) The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is a monomethanesulfonate salt.

**Claim 4.** (currently amended) The [[A]] method of claim 1, 2 or 3, wherein the inflammation involves monocytes.

**Claim 5.** (currently amended) The method of claim 4 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

**Claim 6.** (original) The method of claim 4 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

**Claim 7.** (original) The method of claim 1 wherein the inflammation is chronic.

**Claim 8.** (original) The method of claim 1 wherein the inflammation is acute.

**Claim 9.** (original) The method of claim 1 wherein the subject is a mammal.

**Claim 10.** (original) The method of claim 9 wherein the subject is a human subject.

**Claim 11.** (amended) The method of claim 1, ~~2, or 3~~ wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

**Claim 12.** (original) The method of claim 11 wherein the anti-imflammatory effective amount is in the range from 50 mg to 600 mg.

**Claims 13-27** (canceled)

**Claim 28.** (new) The method of claim 2 wherein the inflammation involves monocytes.

**Claim 29.** (new) The method of claim 28 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

**Claim 30.** (new) The method of claim 28 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

**Claim 31.** (new) The method of claim 3, wherein the inflammation involves monocytes.

**Claim 32.** (new) The method of claim 31 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

**Claim 33.** (new) The method of claim 31 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

**Claim 34.** (new) The method of claim 2 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

Application No. Not yet assigned  
Preliminary Amdt. dated December 21, 2004

**Claim 35. (new)** The method of claim 3 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.